20May 2023
Variation in Early Anakinra Use and Short‐Term Outcomes in Multisystem Inflammatory Syndrome in Children

Variation in Early Anakinra Use and Short‐Term Outcomes in Multisystem Inflammatory Syndrome in Children

This study aimed to investigate the use of interleukin-1 receptor antagonism with anakinra in treating multisystem inflammatory syndrome in children (MIS-C) and its impact on cardiovascular outcomes. The retrospective cohort study analyzed MIS-C cases from a US surveillance registry between November 2020 and December 2021. Factors influencing the initial use of anakinra were identified, and outcomes were compared between patients receiving anakinra plus intravenous immunoglobulin (IVIG) and/or glucocorticoids versus those receiving only IVIG and glucocorticoids. The study found significant variation in the use of anakinra among patients but no significant improvement in cardiovascular outcomes with early addition of anakinra to standard therapy compared to standard therapy alone.

  • #rheumatology

Like

Save

Share